Tokai initiates trial of galeterone in men with AR-V7-positive mCRPC

According to information released earlier today by Tokai Pharmaceuticals, the company has started to enroll patients with AR-V7-positive, metastatic, castration-resistant prostate cancer (mCRPC) into a randomized Phase III clinical trial of treatment with galeterone. … READ MORE …

NICE rejects coverage of enzalutamide in men with chemo-naive mCRPC

According to a report on Yahoo!News, the National Institute for Care and Health Excellence (NICE) in the UK has issued draft guidance suggesting that enzalutamide is not sufficiently cost-effective for use in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

CRPC, “personalized” medicine, and the science of whack a mole

We have known for decades that prostate cancer is an “evolutionary” cancer. In other words, clinically significant prostate cancer and prostate cancer-specific mortality are the consequence of a series of events over time (probably both genetic and epigenetic) that lead to progressive and then to metastatic disease of variable levels of aggression. … READ MORE …

TARP trial shows limited benefits from 5-ARI + an anti-androgen in CRPC

For some 15+ years there have been subsets of patients and physicians who have believed strongly that adding a 5α-reductase inhibitor (5-ARI) like finasteride or dutasteride to an anti-androgen would quite certainly aid in the prevention of prostate cancer progression because such a regimen would reduce levels of dihydrotestosterone. … READ MORE …

International group creates better gene map for men with mCRPC

A new article in the journal Cell is being said to “clarify the genetic backgrounds of men with metastatic, castration-resistant prostate cancer” (mCRPC). It also suggests that most cases of prostate cancer are “sensitive to drugs already available or under development.” … READ MORE …

STRIVE trial again shows benefits to enzalutamide vs. bicalutamide

Earlier this year results from the TERRAIN trial reported that adding enzalutamide (Xtandi) to LHRH agonist therapy was more effective than adding the antiandrogen bicalutamide in men with metastatic, castration-resistant prostate cancer ( M1 CRPC). … READ MORE …

Crowdsourcing to fund prostate cancer trials … can this be made to work?

The motivated son of a man with late-stage prostate cancer has put together a crowdsourcing campaign to raise at least $1 million to fund what appears to be a Phase II clinical trial of the use of disulfiram in the treatment of castration-resistant prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,342 other followers